In Wednesday’s session, Arbutus Biopharma Corporation (NASDAQ:ABUS) marked $2.70 per share, up from $2.66 in the previous session. While Arbutus Biopharma Corporation has overperformed by 1.50%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABUS fell by -13.46%, with highs and lows ranging from $6.50 to $1.85, whereas the simple moving average jumped by 6.37% in the last 200 days.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
On February 02, 2022, Jefferies Upgraded Arbutus Biopharma Corporation (NASDAQ: ABUS) to Buy. A report published by Jefferies on February 25, 2021, Initiated its previous ‘Hold’ rating for ABUS. H.C. Wainwright also rated ABUS shares as ‘Buy’, setting a target price of $10 on the company’s shares in an initiating report dated December 17, 2020. JMP Securities Initiated an Mkt Outperform rating on July 27, 2020, and assigned a price target of $8. Robert W. Baird July 24, 2020d its ‘Outperform’ rating to ‘Neutral’ for ABUS, as published in its report on July 24, 2020. Chardan Capital Markets also rated the stock as ‘Buy’.
Analysis of Arbutus Biopharma Corporation (ABUS)
Further, the quarter-over-quarter increase in sales is 81.80%, showing a positive trend in the upcoming months.
Arbutus Biopharma Corporation’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -43.80% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and ABUS has an average volume of 857.51K. Furthermore, long-term investors anticipate a median target price of $5.40, showing growth from the present price of $2.70, which can serve as yet another indication of whether ABUS is worth investing in or should be passed over.
How Do You Analyze Arbutus Biopharma Corporation Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 25.77%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 30.00% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ABUS shares?
The recent increase in stakes in ABUS appears to be a result of several institutional investors and hedge funds increasing their positions. BlackRock Fund Advisors’s position in ABUS has decreased by -1.56% in the first quarter. The company now owns 6,809,434 shares of the stock, with a value of $15.93 million, following the sale of -107,727 additional shares during the last quarter. Two Seas Capital LP made another increased to its shares in ABUS during the first quarter, upping its stake by 61.45%. During the last quarter, the company picked up 2,152,041 additional shares for a total stake of worth $13.23 million, bringing number of shares owned by the company to 5,653,917.
During the first quarter, The Vanguard Group, Inc. added a 61,806 position in ABUS. Hudson Bay Capital Management LP purchased an additional 0.29 million shares in the last quarter, increasing its holdings by 6.29%, now holding 4.96 million shares worth $11.61 million. At the end of the first quarter, Millennium Management LLC decreased its ABUS holdings by -15.60% and now holds 3.51 million ABUS shares valued at $8.21 million with the lessened -0.65 million shares during the period. ABUS shares are owned by institutional investors to the tune of 30.00% at present.